Detail akcie Exelixis online

Business Summary: Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has four products, including its flagship molecule, cabozantinib, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.
Financial Summary: BRIEF: For the 13 weeks ended 31 March 2023, Exelixis Inc revenues increased 15% to $408.8M. Net income decreased 42% to $40M. Revenues reflect CABOMETYX segment increase of 19% to $361.8M, License revenues segment increase of 21% to $29.8M, U.S segment increase of 17% to $367.4M, Japan segment increase of 6% to $7.8M. Net income was offset by Other Research and development increase of 56% to $231M (expense).